📊 Module 01 · Launch Readiness

8-Dimension Launch Readiness Scorecard

Comprehensive launch readiness assessment across Brand Strategy, Medical Affairs, Market Access, Commercial, Operations, Communications & Digital, KOL Engagement, and Regulatory readiness.

Composite Readiness

72%

target ≥ 85% at L-90

▲ Below target

Days to Launch

187

L-187

Critical Risks

3

red status

▲ Escalate

Launch Confidence

Yellow

go/no-go @ L-90

🎯 8-Dimension Readiness DetailL-187 status

Dimension	Score	Lead Owner	Status	Key Gaps / Actions	Risk
Brand Strategy & Positioning	88	VP Marketing	Green	Positioning locked, brand book v2 in distribution	Low
Medical Affairs Readiness	82	VP Medical Affairs	Green	MSL deployment 90%, scientific platform locked	Low
Market Access & Reimbursement	68	VP Market Access	Yellow	Medicaid PA strategy pending in 12 states	Medium
Commercial Operations	78	VP Commercial	Green	SFE deployment 85%, IC plan finalized	Low
Supply Chain & Operations	54	VP Operations	Red	CMC bottleneck — second site validation behind schedule	High
Communications & Digital	72	VP Communications	Yellow	HCP digital campaign in development; DTC creative pending MLR	Medium
KOL Engagement	85	VP Medical Affairs	Green	Tier 1 KOLs 95% engaged, Tier 2 advisory board planned	Low
Regulatory & Compliance	58	VP Regulatory	Red	FDA labeling negotiation ongoing; promotional materials on hold	High

🕸️ Readiness Radar

📈 Readiness Trajectory (vs Plan)

⚡ Launch Readiness Strategic Brief

Composite readiness at 72% versus 85% target at L-90 places launch at YELLOW with two RED dimensions requiring immediate escalation:

Supply Chain RED (54%): Second manufacturing site validation 8 weeks behind schedule. Recommend interim single-site supply strategy with phased market expansion; engage CMO partner as Phase 1 backup. Escalate to CEO.
Regulatory RED (58%): FDA labeling negotiation centers on pneumonitis warning language. Recommend in-person meeting with reviewer Q4 2026; prepare promotional materials in 2 versions (current + likely-final labels) to avoid post-approval delay.
Medicaid PA strategy: 12 states behind on PA criteria definition. Recommend NCQA-aligned PA template + state-by-state rollout vs. state-by-state custom development.

Critical path to GREEN: resolve supply by L-150, regulatory by L-120. Failure to address either pushes launch by an estimated 3-6 months ($380-540M revenue impact).

🌍 Module 02 · Country Sequencing

Global Country Launch Sequencing

Wave-based launch sequencing optimizing for regulatory approval timing, payer access, competitive landscape, and international reference pricing implications.

Launch Markets

28

across 3 waves

Wave 1 Markets

5

months 0-6 post-approval

Time to 90% Coverage

18

months

Peak Yr 5 Revenue

$3.8B

global

📅 Country Launch Sequence

🇺🇸 United States

M0

🇩🇪 Germany

M1

🇬🇧 United Kingdom

M2

🇯🇵 Japan

M3

🇨🇦 Canada

M5

🇫🇷 France

M6

🇮🇹 Italy

M8

🇪🇸 Spain

M9

🇦🇺 Australia

M10

🇰🇷 South Korea

M11

🇧🇷 Brazil

M13

🇨🇳 China (NMPA)

M15

🇲🇽 Mexico

M16

🇮🇳 India

M18

🗺️ Wave Strategy & Rationale

Wave	Markets	Timing	Yr-5 Peak Sales	Strategic Rationale
Wave 1	US, Germany, UK, Japan, Canada	M0-M5	$2.4B (63%)	Highest revenue + reference price anchors; US drives ROI
Wave 2	France, Italy, Spain, Australia, S. Korea	M6-M11	$890M (23%)	EU5 completion; price-friendly HTAs first
Wave 3	Brazil, China, Mexico, India + 14 more	M12-M24	$510M (14%)	Emerging markets; partner with local affiliates / distributors

⚡ Sequencing Strategic Brief

Anchor sequence (US → Germany → UK → Japan) protects international reference pricing while capturing 63% of peak sales in Wave 1. Three sequencing risks:

UK price erosion: Launching UK before Germany would anchor international reference at NICE-discounted price. Confirmed Germany-first sequencing protects ~$340M cumulative revenue.
Japan timing: PMDA approval expected M3, but reimbursement (Chuikyo) decision lags 60-90 days. Plan promotional launch at NHI listing, not approval.
China (NMPA) Wave 3: Significant ($120M Yr-3) but requires local Phase 3 bridging trial in 30% of cases. If bridging required, delays to M18+.

👥 Module 03 · KOL & Advocacy

Pre-Launch KOL Engagement & Advocacy Strategy

KOL identification, tiering, engagement plan, and patient advocacy organization mapping for pre-launch and launch readiness.

Tier 1 KOLs

24

global influencers

KOL Engagement Rate

87%

advisory board attendance

Advocacy Orgs

12

partnerships

Speaker Bureau

68

certified speakers

⭐ Top KOLs by Therapeutic Area — NSCLC

KOL	Institution	Country	Influence Score	Engagement Status	Activities (12 mo)
Dr. R. Herbst	Yale Cancer Center	🇺🇸 US	96	Tier 1 · Engaged	Advisory + speaker + congress
Dr. S. Peters	CHUV Lausanne	🇨🇭 Switzerland	94	Tier 1 · Engaged	Steering committee chair
Dr. A. Drilon	MSK Cancer Center	🇺🇸 US	92	Tier 1 · Engaged	Advisory + publication
Dr. F. Cappuzzo	National Cancer Institute Roma	🇮🇹 Italy	88	Tier 1 · Engaged	Advisory + speaker
Dr. T. Mok	Chinese University of Hong Kong	🇭🇰 HK	95	Tier 1 · Engaged	APAC steering
Dr. M. Reck	LungenClinic Grosshansdorf	🇩🇪 Germany	82	Tier 2 · Pending	Advisory board invitation
Dr. R. Soo	National University Hospital Singapore	🇸🇬 SG	78	Tier 2 · Engaged	Speaker training Q3
Dr. J. Garon	UCLA Jonsson Cancer Center	🇺🇸 US	80	Tier 2 · Engaged	Speaker + publication

⚡ KOL Engagement Strategic Brief

Tier 1 engagement is strong at 87%. Three priority gaps:

Dr. Reck (Tier 2 · pending): Highest-profile German thoracic oncologist not yet on advisory board. Recommend personalized outreach by Chief Medical Officer at WCLC 2026.
Tier 3 / community oncologist gap: Speaker bureau over-indexed on academic centers (64% academic, 36% community). Recommend community oncologist recruitment for post-launch peer-to-peer programs.
Advocacy partnership opportunity: LUNGevity, Free to Breathe, and IASLC Foundation have not yet committed to launch awareness campaigns. Recommend grant + co-development of patient-facing educational materials.

🗺️ Module 04 · Optimized Brand Roadmap

Optimized Brand Roadmap (OBR)

Integrated launch and post-launch milestone roadmap covering pre-launch (L-12 to L-0), launch (L-0 to L+90), and growth phases (L+90 to L+360).

⏱️ Pre-Launch Milestones (L-12 to L-0)

Milestone	Timing	Owner	Dependency	Status
FDA approval (PDUFA)	L-0	Regulatory	Label finalization	In progress
Brand strategy lockdown	L-9	Marketing	Market research complete	Complete
MLR approval of launch materials	L-3	MLR Committee	Label content	In review
Field force hire & train	L-6 to L-1	Sales Ops	FF deployment plan	In progress
Manufacturing scale-up validation	L-9	CMC	Site 2 PAI	Delayed
Payer dossier delivery (AMCP)	L-6	Market Access	HEOR completion	Complete
KOL advisory board (final)	L-4	Medical Affairs	Final clinical data	Complete
HCP digital campaign go-live	L-2	Digital	MLR approval	In progress

🚀 Launch & Post-Launch (L-0 to L+360)

Phase	Milestone	Target Metric	Year 1 Goal
Launch Day (L+0)	FF detail launch + advocacy event	HCP awareness	40% target HCP awareness
L+30 days	First prescription	Initial Rx volume	500 Rx
L+90 days	Q1 launch review	Trial vs forecast	±15% of forecast
L+180 days	Half-year review + adjustments	Market share	8% NRx share
L+270 days	Real-world data emergence	RWE publications	2+ abstracts
L+360 days	Year-1 launch debrief	Yr-1 revenue	$280M

📈 Module 05 · Trajectory Modeling

Year 1-3 Launch Trajectory Forecast

Risk-adjusted revenue trajectory across base, optimistic, and conservative scenarios. Peer benchmarking against analogous launches.

Year 1 Forecast

$280M

base case

Year 3 Forecast

$1.6B

base case

Peak Year (Yr 7)

$3.8B

global net

Peer Bench (Yr 1)

$245M

median analogue

📊 3-Year Revenue Trajectory (Scenarios)

📊 Peer Launch Comparison

🔍 Launch Trajectory Drivers

Driver	Yr-1 Impact	Confidence
Payer access ramp	+18%	High
HCP awareness/adoption	+14%	High
Sales force productivity	+12%	Med
Competitive response	-8%	Med
Supply / inventory	-4%	High
Real-world effectiveness signals	+6%	Med

⚡ Trajectory Strategic Brief

Base-case Year 1 of $280M tracks 14% above peer median ($245M) reflecting strong clinical differentiation and payer access. Three trajectory levers:

Aggressive scenario ($340M Yr 1): Requires accelerated Medicaid PA resolution + Tier-3 formulary positioning at top 5 PBMs by L+60.
Conservative scenario ($210M Yr 1): Triggered by supply constraint or labeling delay. Prepare investor narrative + revised guidance protocols in advance.
Competitive risk: Two competitive late-stage Phase 3 assets read out in Year 2. Forecast assumes -8% impact; could swing to -15% if both data are positive. Refresh forecast quarterly.